Literature DB >> 15060062

Interleukin-3 binding to the murine betaIL-3 and human betac receptors involves functional epitopes formed by domains 1 and 4 of different protein chains.

James M Murphy1, Sally C Ford, Jane E Olsen, Sonja E Gustin, Peter D Jeffrey, David L Ollis, Ian G Young.   

Abstract

Interleukin-3 (IL-3) is a cytokine produced by activated T-cells and mast cells that is active on a broad range of hematopoietic cells and in the nervous system and appears to be important in several chronic inflammatory diseases. In this study, alanine substitutions were used to investigate the role of residues of the human beta-common (hbetac) receptor and the murine IL-3-specific (beta(IL-3)) receptor in IL-3 binding. We show that the domain 1 residues, Tyr(15) and Phe(79), of the hbetac receptor are important for high affinity IL-3 binding and receptor activation as shown previously for the related cytokines, interleukin-5 and granulocyte-macrophage colony-stimulating factor, which also signal through this receptor subunit. From the x-ray structure of hbetac, it is clear that the domain 1 residues cooperate with domain 4 residues to form a novel ligand-binding interface involving the two protein chains of the intertwined homodimer receptor. We demonstrate by ultracentrifugation that the beta(IL-3) receptor is also a homodimer. Its high sequence homology with hbetac suggests that their structures are homologous, and we identified an analogous binding interface in beta(IL-3) for direct IL-3 binding to the high affinity binding site in hbetac. Tyr(21) (A-B loop), Phe(85), and Asn(87) (E-F loop) of domain 1; Ile(320) of the interdomain loop; and Tyr(348) (B'-C' loop) and Tyr(401) (F'-G' loop) of domain 4 were shown to have critical individual roles and Arg(84) and Tyr(317) major secondary roles in direct murine IL-3 binding to the beta(IL-3)receptor. Most surprising, none of the key residues for direct IL-3 binding were critical for high affinity binding in the presence of the murine IL-3 alpha receptor, indicating a fundamentally different mechanism of high affinity binding to that used by hbetac.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15060062     DOI: 10.1074/jbc.M402705200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  An improved resolution structure of the human beta common receptor involved in IL-3, IL-5 and GM-CSF signalling which gives better definition of the high-affinity binding epitope.

Authors:  P D Carr; F Conlan; S Ford; D L Ollis; I G Young
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-05-31

2.  Two modes of beta-receptor recognition are mediated by distinct epitopes on mouse and human interleukin-3.

Authors:  Shamaruh Mirza; Jinglong Chen; Bin Wen; Cameron L Ewens; Jin Dai; James M Murphy; Ian G Young
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

3.  The role of interchain heterodisulfide formation in activation of the human common beta and mouse betaIL-3 receptors.

Authors:  Shamaruh Mirza; Jinglong Chen; James M Murphy; Ian G Young
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

4.  Slow-dissociation effect of common signaling subunit beta c on IL5 and GM-CSF receptor assembly.

Authors:  Tetsuya Ishino; Adrian E Harrington; Meirav Zaks-Zilberman; Jeffery J Scibek; Irwin Chaiken
Journal:  Cytokine       Date:  2008-02-21       Impact factor: 3.861

5.  Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging.

Authors:  Meirav Zaks-Zilberman; Adrian E Harrington; Tetsuya Ishino; Irwin M Chaiken
Journal:  J Biol Chem       Date:  2008-03-07       Impact factor: 5.157

6.  High yield production of a soluble human interleukin-3 variant from E. coli with wild-type bioactivity and improved radiolabeling properties.

Authors:  Timothy R Hercus; Emma F Barry; Mara Dottore; Barbara J McClure; Andrew I Webb; Angel F Lopez; Ian G Young; James M Murphy
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

7.  A cytokine-cytokine interaction in the assembly of higher-order structure and activation of the interleukine-3:receptor complex.

Authors:  Raja Dey; Kunmei Ji; Zhigang Liu; Lin Chen
Journal:  PLoS One       Date:  2009-04-07       Impact factor: 3.240

8.  CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.

Authors:  Con Panousis; Urmi Dhagat; Kirsten M Edwards; Veronika Rayzman; Matthew P Hardy; Hal Braley; Gail M Gauvreau; Timothy R Hercus; Steven Smith; Roma Sehmi; Laura McMillan; Mara Dottore; Barbara J McClure; Louis J Fabri; Gino Vairo; Angel F Lopez; Michael W Parker; Andrew D Nash; Nicholas J Wilson; Michael J Wilson; Catherine M Owczarek
Journal:  MAbs       Date:  2015-12-14       Impact factor: 5.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.